Factors affecting the fate of faecal diversion in patients with perianal crohn's disease

Colorectal Disease

Volumn 17, Issue 1, 2015, Pages 66-72

  Gu, J ^a   Valente, M A ^a   Remzi, F H ^a   Stocchi, L ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Biological therapy; Crohn's proctitis; Faecal diversion; Perianal crohn's disease

Indexed keywords

ADULT; ANUS DISEASE; ARTICLE; COLOSTOMY; CROHN DISEASE; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; ILEOSTOMY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PATIENT CARE; PERIANAL ABSCESS; PERIANAL CROHN DISEASE; PRIORITY JOURNAL; RECTUM RESECTION; UNIVARIATE ANALYSIS; ANALYSIS OF VARIANCE; ANUS DISEASES; COMPLICATION; MIDDLE AGED; PATHOLOGY; PROCTITIS; PROSPECTIVE STUDY; RECURRENT DISEASE; SEVERITY OF ILLNESS INDEX; STOMA; TREATMENT OUTCOME;

ADULT; ANALYSIS OF VARIANCE; ANUS DISEASES; COLOSTOMY; CROHN DISEASE; FEMALE; HUMANS; ILEOSTOMY; MALE; MIDDLE AGED; PROCTITIS; PROSPECTIVE STUDIES; RECURRENCE; SEVERITY OF ILLNESS INDEX; SURGICAL STOMAS; TREATMENT OUTCOME;

EID: 84925867788     PISSN: 14628910     EISSN: 14631318     Source Type: Journal    
DOI: 10.1111/codi.12796     Document Type: Article

References (26)

1. Ruffolo C, Citton M, Scarpa M et al. Perianal Crohn's disease: is there something new? World J Gastroenterol 2011; 17: 1939-46.
2. Eglinton TW, Barclay ML, Gearry RB, Frizelle FA. The spectrum of perianal Crohn's disease in a population-based cohort. Dis Colon Rectum 2012; 55: 773-7.
3. Beaugerie L, Seksik P, Nion-Larmurier I, Gendre JP, Cosnes J. Predictors of Crohn's disease. Gastroenterology 2006; 130: 650-6.
4. Gelbmann CM, Rogler G, Gross V et al. Prior bowel resections, perianal disease, and a high initial Crohn's disease activity index are associated with corticosteroid resistance in active Crohn's disease. Am J Gastroenterol 2002; 97: 1438-45.
5. Sandborn WJ, Fazio VW, Feagan BG, Hanauer SB. AGA technical review on perianal Crohn's disease. Gastroenterology 2003; 125: 1508-30.
6. Wiese DM, Schwartz DA. Managing perianal Crohn's disease. Curr Gastroenterol Rep 2012; 14: 153-61.
7. Yamamoto T, Allan RN, Keighley MR. Effect of fecal diversion alone on perianal Crohn's disease. World J Surg 2000; 24: 1258-62; discussion 62-3.
8. Edwards CM, George BD, Jewell DP, Warren BF, Mortensen NJ, Kettlewell MG. Role of a defunctioning stoma in the management of large bowel Crohn's disease. Br J Surg 2000; 87: 1063-6.
9. Regimbeau JM, Panis Y, Cazaban L et al. Long-term results of faecal diversion for refractory perianal Crohn's disease. Colorectal Dis 2001; 3: 232-7.
10. Galandiuk S, Kimberling J, Al-Mishlab TG, Stromberg AJ. Perianal Crohn disease: predictors of need for permanent diversion. Ann Surg 2005; 241: 796-801; discussion 801-2.
11. Mueller MH, Geis M, Glatzle J et al. Risk of fecal diversion in complicated perianal Crohn's disease. J Gastrointest Surg 2007; 11: 529-37.
12. Hong MK, Craig LA, Bell S et al. Faecal diversion in the management of perianal Crohn's disease. Colorectal Dis 2011; 13: 171-6.
13. Talbot C, Sagar PM, Johnston MJ, Finan PJ, Burke D. Infliximab in the surgical management of complex fistulating anal Crohn's disease. Colorectal Dis 2005; 7: 164-8.
14. Topstad DR, Panaccione R, Heine JA, Johnson DR, MacLean AR, Buie WD. Combined seton placement, infliximab infusion, and maintenance immunosuppressives improve healing rate in fistulizing anorectal Crohn's disease: a single center experience. Dis Colon Rectum 2003; 46: 577-83.
15. Tursi A, Papa A, Maiorano M. Onset of severe perianal disease in Crohn's disease under treatment with infliximab: successful treatment with adalimumab and setons drainage. Inflamm Bowel Dis 2011; 17: 676-8.
16. Hanauer SB, Feagan BG, Lichtenstein GR et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-9.
17. Kiran RP, Kirat HT, Rottoli M, Xhaja X, Remzi FH, Fazio VW. Permanent ostomy after ileoanal pouch failure: pouch in situ or pouch excision? Dis Colon Rectum 2012; 55: 4-9.
18. Figg RE, Church JM. Perineal Crohn's disease: an indicator of poor prognosis and potential proctectomy. Dis Colon Rectum 2009; 52: 646-50.
19. Shen B, Remzi FH, Brzezinski A et al. Risk factors for pouch failure in patients with different phenotypes of Crohn's disease of the pouch. Inflamm Bowel Dis 2008; 14: 942-8.
20. Strong SA, Koltun WA, Hyman NH, Buie WD. Practice parameters for the surgical management of Crohn's disease. Dis Colon Rectum 2007; 50: 1735-46.
21. Steele SR, Kumar R, Feingold DL, Rafferty JL, Buie WD. Practice parameters for the management of perianal abscess and fistula-in-ano. Dis Colon Rectum 2011; 54: 1465-74.
22. Korelitz BI, Aronoff J. Crohn's proctitis: a distinct entity. Inflamm Bowel Dis 2010; 16: 721-2.
23. Guidi L, Ratto C, Semeraro S et al. Combined therapy with infliximab and seton drainage for perianal fistulizing Crohn's disease with anal endosonographic monitoring: a single-centre experience. Tech Coloproctol 2008; 12: 111-7.
24. Hyder SA, Travis SP, Jewell DP, McC Mortensen NJ, George BD. Fistulating anal Crohn's disease: results of combined surgical and infliximab treatment. Dis Colon Rectum 2006; 49: 1837-41.
25. Regueiro M, Mardini H. Treatment of perianal fistulizing Crohn's disease with infliximab alone or as an adjunct to exam under anesthesia with seton placement. Inflamm Bowel Dis 2003; 9: 98-103.
26. Tanaka S, Matsuo K, Sasaki T et al. Clinical advantages of combined seton placement and infliximab maintenance therapy for perianal fistulizing Crohn's disease: when and how were the seton drains removed? Hepatogastroenterology 2010; 57: 3-7.